Doxorubicin, vincristine, and cis‐diamminedichloroplatinum (II) therapy in patients with advanced breast cancer

Donald L. Trump, David S. Ettinger, Martin D. Abeloff

Research output: Contribution to journalArticle

Abstract

Preliminary data suggesting synergistic activity of cisplatinum and doxorubicin and the expected poor prognosis of women with breast cancer who progress on treatment with cyclophosphamide, methotrexate and 5‐fluorouracil (CMF), led to a trial of monthly doxorubicin (50 mg/M2), vincristine (1.4 mg/M2) and cisplatinum (50 mg/M2) in such patients. Overall partial response rate to this regimen was 42%; 37% progressed and 21% could not complete two cycles of therapy because of gastrointestinal (three or renal (one) toxicity. This study does not support the use of cisplatinum, 50 mg/M2, in combination with doxorubicin and vincristine in patients with breast cancer which has proven refractory to CMF therapy.

Original languageEnglish (US)
Pages (from-to)1-3
Number of pages3
JournalMedical and Pediatric Oncology
Volume9
Issue number1
DOIs
StatePublished - 1981

Keywords

  • CMF failures
  • breast cancer
  • cisplatinum

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Doxorubicin, vincristine, and cis‐diamminedichloroplatinum (II) therapy in patients with advanced breast cancer'. Together they form a unique fingerprint.

  • Cite this